07-09-2008, 01:07 AM
<b>Obesity in China Doubled in 11 Years With Rising Prosperity </b><!--QuoteBegin-->QUOTE<!--QuoteEBegin-->Obesity among China's 1.3 billion people doubled among women and tripled in men from 1989 to 2000, according to a study published today in the journal Health Affairs. China's rising prosperity, which allows more people to afford meat, dairy foods, vegetable oils and sedentary living, is fueling the growth, the study said.
The number of obese and overweight people in China, now at 325 million, could double in 20 years, spurring more diabetes and heart disease in what was once one of the world's leanest populations
<!--QuoteEnd--><!--QuoteEEnd--><!--QuoteBegin-->QUOTE<!--QuoteEBegin-->``<b>The prevalence of hypertension has exploded and every day, China and India are producing more than half of the new cases of diabetes diagnosed daily,'' </b>said Popkin.<!--QuoteEnd--><!--QuoteEEnd--><!--QuoteBegin-->QUOTE<!--QuoteEBegin-->Pfizer, the world's largest drugmaker, has invested $500 million in China in the last 15 years, the New York-based company said. Astra-Zeneca Plc's China sales more than quadrupled from $85 million in 2001 to $422 million in 2007, said Zhou Yi, spokeswoman for the London-based company, in an e- mail.<!--QuoteEnd--><!--QuoteEEnd-->
The number of obese and overweight people in China, now at 325 million, could double in 20 years, spurring more diabetes and heart disease in what was once one of the world's leanest populations
<!--QuoteEnd--><!--QuoteEEnd--><!--QuoteBegin-->QUOTE<!--QuoteEBegin-->``<b>The prevalence of hypertension has exploded and every day, China and India are producing more than half of the new cases of diabetes diagnosed daily,'' </b>said Popkin.<!--QuoteEnd--><!--QuoteEEnd--><!--QuoteBegin-->QUOTE<!--QuoteEBegin-->Pfizer, the world's largest drugmaker, has invested $500 million in China in the last 15 years, the New York-based company said. Astra-Zeneca Plc's China sales more than quadrupled from $85 million in 2001 to $422 million in 2007, said Zhou Yi, spokeswoman for the London-based company, in an e- mail.<!--QuoteEnd--><!--QuoteEEnd-->